Clinical-stage biotech developing antibody treatments for thyroid eye disease, competing with Amgen's Tepezza.
Clinical-stage biotech developing antibody treatments for thyroid eye disease, competing with Amgen's Tepezza.
No approved product yet, so it earns no sales and is funded by raising capital from investors. The value rests on two antibody drugs aimed at the same cell receptor, IGF-1R, that Tepezza targets, one given by intravenous infusion and one by injection under the skin.
Moat: none (IP / patents). Pre-commercial; must differentiate on dosing convenience versus Amgen's approved Tepezza.
Headquarters: Waltham, Massachusetts, US · Founded: 2020 · Employees: 252
Size Viridian Therapeutics (VRDN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.42B, the 1447th largest of 3,085 United States companies the cockpit tracks. Shares closed at $30.12 on 18 Nov 2026.
Performance Over six months the shares gained 70.8%, against +3.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 62.8% over the last twelve months (peer median +7.9%); the operating margin is -1,781.4% (peer median 13.1%).
Valuation It trades at 106.6× enterprise value to sales against a peer median of 2.8× (most expensive of 16).
Credit Viridian Therapeutics has 1 bond outstanding ($250M).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $26.3M | $70.8M | $302,000 | $314,000 | $1.77M |
| Revenue growth | — | +23,360% | -4% | -82% | — |
| Gross profit | $23.9M | $69.7M | -$938,000 | -$1.01M | $1.02M |
| EBITDA | -$468M | -$362M | -$298M | -$253M | -$134M |
| Net income | -$435M | -$282M | -$209M | -$238M | -$130M |
| Free cash flow | -$344M | -$277M | -$233M | -$185M | -$94.6M |
| Capital expenditure | $1.94M | $495,000 | $511,000 | $898,000 | $797,000 |
| Total debt | $243M | $50.7M | $23.1M | $22.0M | $6.36M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Viridian Therapeutics VRDN | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Immunovant IMVT | $6.86B | -7% | n/a | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VRDN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +34.3% | +1.5% | 2nd highest of 21 |
| 6-month return | +70.8% | +3.4% | 3rd highest of 20 |
| Distance from 52-week high | -12.2% | -22.7% | 7th highest of 21 |
| Revenue growth (TTM) | -62.8% | +7.9% | 2nd lowest of 18 |
| Operating margin | -1,781.4% | 13.1% | lowest of 16 |
| EV / Sales | 106.6× | 2.8× | most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 3.8× | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 2.5× | 4.7% | +4.5% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | 8.1× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 0.3× | -10.0% | +5.4% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 2.2× | -7.5% | -9.6% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
Viridian Therapeutics has 1 bond outstanding with $250M face value.